The Pharmacokinetic Effects and Drug-Drug Interaction of Atorvastatin With Danshensu in Rats

Abstract

Background and Objective: Danshensu and atorvastatin are employed in the management of cardiovascular diseases (CVDs) to lower blood lipid levels and dilate blood vessels. Therefore, this study aimed to examine the potential pharmacokinetic interaction between danshensu and atorvastatin in rats. Materials and Methods: Chromatography was performed using a CORTECST UPLC C18 column (2.1 × 1.5 mm, 1.6 μm) at a temperature of 40 °C. Acetonitrile and water were combined in the mobile phase at a rate of 0.4 mL/min via gradient elution. The methodology was validated under the guidance of the FDA and EMA literature. A total of 12 Sprague-Dawley (SD) rats were randomly assigned into two groups: the experimental group (treated with 150 mg/kg/day danshensu) and the control group (treated with 0.5% CMC-Na). Atorvastatin 10 mg/kg was administered after two weeks. The proposed method meets all the standards of bioanalysis technology verification. Results: Compared to the control group, the experimental group exhibited significant differences in the area under the curve (AUC), t1/2, CLz/F, and Cmax (p < 0.05). The AUC, Cmax, and t1/2 of the experimental group were higher, yet the clearance rate was significantly slowed. Conclusions: This technique was effectively utilized to investigate the pharmacokinetic interaction between danshensu and atorvastatin in rats, which may be of significant clinical importance and contribute to the rationalization of clinical medicine, ultimately facilitating individualized administration.